2. Academic Validation
  3. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer

Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer

  • Future Oncol. 2021 Dec;17(36):5119-5127. doi: 10.2217/fon-2021-0588.
Whitney Rhodes 1,  Richard W DeClue 1,  Neil A Accortt 2,  Ran Jin 2,  Darcie Sandschafer 3,  Debra Wertz 1,  Kashyap Patel 4
Affiliations

Affiliations

  • 1 ConcertAI, 6555 Quince Road, Suite 400, Memphis, TN 38119, USA.
  • 2 Center for Observational Research, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • 3 US Medical Assets, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • 4 Carolina Blood & Cancer Care Associates, 1583 Healthcare Drive Rock Hill, Rock Hill, SC 29732, USA.
PMID: 34698523 DOI: 10.2217/fon-2021-0588
Abstract

Aim: Evaluated real world use of bevacizumab-awwb (MVASI®), a bevacizumab biosimilar, for treating metastatic colorectal Cancer (mCRC). Materials & methods: Adult mCRC patients who received bevacizumab-awwb during the first year after market availability were identified from the ConcertAI oncology dataset. Results: Of 304 patients, 47% initiated bevacizumab-awwb as reference product (RP) naive patients and 53% received bevacizumab-awwb with prior exposure to RP. Overall, 78% received bevacizumab-awwb as first-line therapy; the proportion was higher (91%) in RP-naive patients. Among RP-experienced patients, 83% were transitioned from RP to bevacizumab-awwb in the same line without disease progression; of those, the majority (83%) were transitioned within 28 days. Conclusion: Early evidence from US oncology practices suggests clinical adoption of bevacizumab-awwb in treating mCRC patients.

Keywords

bevacizumab-awwb; biosimilar; metastatic colorectal cancer; real world utilization.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99476
    Anti-VEGFA Antibody